



Transcriptomic clustering of critically ill COVID-19 patients

Cecilia López-Martínez^{1,2,3}, Paula Martín-Vicente^{1,2,3}, Juan Gómez de Oña^{1,4,5}, Inés López-Alonso^{1,2,3,6}, Helena Gil-Peña^{1,7}, Elías Cuesta-Llavona^{1,4}, Margarita Fernández-Rodríguez^{1,3}, Irene Crespo^{1,2,8}, Estefanía Salgado del Riego^{1,9}, Raquel Rodríguez-García^{1,2,10}, Diego Parra^{1,10}, Javier Fernández^{1,11}, Javier Rodríguez-Carrio^{1,8}, Francisco José Jimeno-Demuth¹², Alberto Dávalos¹³, Luis A. Chapado¹³, Eliecer Coto^{1,4,5,14}, Guillermo M. Albaiceta^{1,2,3,8,10,15} and Laura Amado-Rodríguez^{1,2,3,10,14,15}

¹Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain. ²Centro de Investigación Biomédica en Red (CIBER)-Enfermedades Respiratorias, Madrid, Spain. ³Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain. ⁴Servicio de Genética Molecular, Hospital Universitario Central de Asturias, Oviedo, Spain. ⁵Red de Investigación Renal (REDINREN), Madrid, Spain. ⁶Departamento de Morfología y Biología Celular, Universidad de Oviedo, Oviedo, Spain. ⁷Servicio de Pediatría, Hospital Universitario Central de Asturias, Oviedo, Spain. ⁸Departamento de Biología Funcional, Universidad de Oviedo, Oviedo, Spain. ⁹Unidad de Cuidados Intensivos Polivalente, Hospital Universitario Central de Asturias, Oviedo, Spain. ¹⁰Unidad de Cuidados Intensivos Cardiológicos, Hospital Universitario Central de Asturias, Oviedo, Spain. ¹¹Servicio de Microbiología, Hospital Universitario Central de Asturias, Oviedo, Spain. ¹²Servicio de Informática, Hospital Universitario Central de Asturias, Oviedo, Spain. ¹³Instituto Madrileño de Estudios Avanzados (IMDEA) Alimentación, CEI UAM+CSIC, Madrid, Spain. ¹⁴Departamento de Medicina, Universidad de Oviedo, Oviedo, Spain. ¹⁵G.M. Albaiceta and L. Amado-Rodríguez share last authorship.

Corresponding author: Guillermo M. Albaiceta (gma@crit-lab.org)



Shareable abstract (@ERSpublications)

Gene expression in peripheral blood determines two clusters of critically ill COVID-19 patients with different pathogenesis and outcomes <https://bit.ly/3QLEld7>

Cite this article as: López-Martínez C, Martín-Vicente P, Gómez de Oña J, et al. Transcriptomic clustering of critically ill COVID-19 patients. *Eur Respir J* 2023; 61: 2200592 [DOI: 10.1183/13993003.00592-2022].

This single-page version can be shared freely online.

Copyright ©The authors 2023.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org

This article has an editorial commentary:
<https://doi.org/10.1183/13993003.02008-2022>

Received: 20 March 2022
Accepted: 19 Aug 2022

Abstract

Background Infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may cause a severe disease, termed coronavirus disease 2019 (COVID-19), with significant mortality. Host responses to this infection, mainly in terms of systemic inflammation, have emerged as key pathogenetic mechanisms and their modulation has shown a mortality benefit.

Methods In a cohort of 56 critically ill COVID-19 patients, peripheral blood transcriptomes were obtained at admission to an intensive care unit (ICU) and clustered using an unsupervised algorithm. Differences in gene expression, circulating microRNAs (c-miRNAs) and clinical data between clusters were assessed, and circulating cell populations estimated from sequencing data. A transcriptomic signature was defined and applied to an external cohort to validate the findings.

Results We identified two transcriptomic clusters characterised by expression of either interferon-related or immune checkpoint genes, respectively. Steroids have cluster-specific effects, decreasing lymphocyte activation in the former but promoting B-cell activation in the latter. These profiles have different ICU outcomes, despite no major clinical differences at ICU admission. A transcriptomic signature was used to identify these clusters in two external validation cohorts (with 50 and 60 patients), yielding similar results.

Conclusions These results reveal different underlying pathogenetic mechanisms and illustrate the potential of transcriptomics to identify patient endotypes in severe COVID-19 with the aim to ultimately personalise their therapies.

